Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 4/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 2/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30858862 | 1.00 | RXRA (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL23043800 | 0.88 | CYP4F2 (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30392077 | 0.88 | CYP4F2 (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL31093701 | 0.87 | CYP4F2 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL31015405 | 0.85 | PDE1B (0.36) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30797632 | 0.84 | CREBBP (0.35) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL27165299 | 0.84 | RXRA (0.35) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL15229935 | 0.84 | RXRA (0.35) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29734718 | 0.84 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL26920565 | 0.84 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| EP-3215156-B1 | INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE | IOMET PHARMA LTD (GB) | 2025-09-24 | — | — | EP | disclosed |
| EP-4581024-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024047135-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-03-07 | — | — | WO | disclosed |
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| CN-111943890-A | Pharmaceutical compounds | 艾欧米制药有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-107108556-B | Pharmaceutical compounds | 艾欧米制药有限公司 | 2020-09-29 | — | — | CN | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20180354908-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | RXRA 1042/4885RXRB 912/4885RXRG 790/4885 |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | KRAS, NRAS, HRAS | RXRA 2971/4885RXRB 2727/4885RXRG 3222/4885 |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | RXRA 1042/4885RXRB 912/4885RXRG 790/4885 |
| US-10590086-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | RXRA 1042/4885RXRB 912/4885RXRG 790/4885 |
| US-20180354908-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | RXRA 1042/4885RXRB 912/4885RXRG 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.